Overview


According to FutureWise analysis, the market for Breast Cancer Diagnostics is expected to grow at a CAGR of 7% over the forecast period of 2023-2031.

Breast cancer is a condition in which malignant cells proliferate unchecked in the breast tissue more frequently in women than in males. Breast cells, the most prevalent cells in the mammary glands and ducts, divide uncontrollably to cause breast cancer. A lump or lump in the breast, a bloody flow from the nipple, and a change in the contour of the nipple or breast are some signs of breast cancer. Treatment for breast cancer is based on the cancer's stage. Chemotherapy, radiation therapy, and surgery are the main forms of treatment. Effective cancer treatment depends on the early diagnosis of carcinoma. Additionally, early disease detection improves outcomes by opening up a wide range of therapeutic options, improving survival rates, and improving quality of life. The constantly expanding prevalence of diseases has increased the demand and need for novel treatments or diagnostic methods.

Breast cancer can occur in healthy individuals for various reasons, including limited physical activity, alcohol usage, obesity, menopause, biological history, and childbirth at an older age. Early detection of breast cancer is possible with some screening procedures such as annual mammograms, CT scans, and MRIs. An individual is encouraged to have a diagnostic test to confirm the suspicions of breast cancer if the symptoms are visibly apparent. The majority of these diagnostic procedures involve a biopsy, in which a small sample of internal tissue from the patient's body is taken and examined under a microscope to identify breast cancer. This diagnostic procedure can be carried out using several choices, including those offered by the breast cancer diagnostic market, such as biopsy, clinical lab tests, and ultrasound techniques.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Breast Cancer Diagnostics Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Breast Cancer Diagnostics Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

  • Hologic Inc.
  • GE Healthcare
  • Phillips Healthcare
  • Fujifilm Holdings Corporation
  • Gamma Medica Inc.
  • Toshiba Corporation
  • Aurora Imaging Technology Inc.
  •  Dilion Technologies Inc.
  • Abbott
  • F. Hoffmann-La Roche Ltd
  • Thermo Fisher Scientific Inc.
  • Siemens AG
  • Illumina, Inc.

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Diagnostic Type

  • Ionizing breast imaging technologies
    • Analog Mammography
    • Full-field digital mammography (FFDM)3D breast tomosynthesis
    • Positron emission tomography/ Computed tomography (PET/CT)
    • Molecular Breast imaging/ breast specific gamma imaging (MBI/BSMI)
    • Positron emission mammography
    • Others
  • Non-ionizing imaging technologies
    • Breast MRI (Magnetic Resonance Imaging)
    • Breast Ultrasound
    • Optical Imaging
    • Automated whole breast ultrasound (AWBU)
    • Breast thermography

By End User

  • Hospitals
  • Cancer research centers/ institutes
  • Diagnostic Clinical laboratories
  • Ambulatory Surgical centers

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of region will also be provided in the final version of this market which is based on conclusion of primary interviews and secondary data point gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America registered the highest share in the market in 2022. The existence of significant players, a well-established diagnostic and screening infrastructure, technology breakthroughs, a high patient awareness level, and favorable reimbursement guidelines are the main elements influencing the region's dominance.

Additionally, based on end-user; hospitals account for the largest share in the market. The segment's demand is expected to be fuelled by rising hospitalization rates for patients and the burden of disease. Patients are subjected to biopsy for follow-up testing in hospitals after the screening test. Additionally, the course of the disease and the evaluation of the efficacy of cancer treatment are monitored using PET, CT, and MRI in the hospitals.

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants
  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth
  • To provide with an exhaustive analysis on the Breast Cancer Diagnostics Market By Diagnostic Type, By End User and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions
  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Breast Cancer Diagnostics Market Variables, Trends and Scope
    •         1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Type Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Breast Cancer Diagnostics Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework

  • 6.   Breast Cancer Diagnostics Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Type Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Type Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Breast Cancer Diagnostics Market, By Diagnostic Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Ionizing breast imaging technologies
         1.1. Analog Mammography
         1.2. Full-field digital mammography (FFDM)
         1.3. 3D breast tomosynthesis
         1.4. Positron emission tomography/ Computed tomography (PET/CT)
         1.5. Molecular Breast imaging/ breast specific gamma imaging (MBI/BSMI)
         1.6. Positron emission mammography
         1.7. Others
        2. Non-ionizing imaging technologies
         2.1. Breast MRI (Magnetic Resonance Imaging)
         2.2. Breast Ultrasound
         2.3. Optical Imaging
         2.4. Automated whole breast ultrasound (AWBU)
         2.5. Breast thermography

  • 8.   Breast Cancer Diagnostics Market, By End User Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospitals
        2. Cancer research centers/ institutes
        3. Diagnostic Clinical laboratories
        4. Ambulatory Surgical centers

  • 9.   North America Breast Cancer Diagnostics Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 10.   Latin America Breast Cancer Diagnostics Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 11.   Europe Breast Cancer Diagnostics Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 12.   Asia Pacific Breast Cancer Diagnostics Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 13.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 14.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 15.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Hologic Inc.
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. GE Healthcare
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Phillips Healthcare
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Fujifilm Holdings Corporation.
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Gamma Medica Inc.
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Toshiba Corporation
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Aurora Imaging Technology Inc.
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Dilion Technologies Inc.
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Abbott
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. F. Hoffmann-La Roche Ltd
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
        11. Illumina, Inc.
         11.1. Company Overview
         11.2. Product Portfolio
         11.3. SWOT Analysis
         11.4. Financial Overview
         11.5. Strategic Overview
        12. Thermo Fisher Scientific Inc.
         12.1. Company Overview
         12.2. Product Portfolio
         12.3. SWOT Analysis
         12.4. Financial Overview
         12.5. Strategic Overview
        13. Siemens AG
         13.1. Company Overview
         13.2. Product Portfolio
         13.3. SWOT Analysis
         13.4. Financial Overview
         13.5. Strategic Overview

  • 16.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nations
  • 17.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients